umirolimus

Trade name: Biolimus

Small moleculeexperimental

Umirolimus is an immunosuppressant, a macrocyclic lactone, a highly lipophilic derivative of sirolimus. This drug is proprietary to Biosensors International, which uses it in its own drug-eluting stents, and licenses it to partners such as Terumo. — Wikipedia

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
4

Earliest trial started Jul 1, 2010 (NCT01502904)

Timeline

No events for the selected filters.

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCOCCO[C@@H]1CC[C@@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](OC)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC
Mol. weight
986.29 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 40-o-(2-ethoxyethyl)rapamycin
  • 42-o-(2-ethoxyethyl) rapamycin
  • biolimus
  • biolimus
  • biolimus a9
  • rapamycin, 42-o-(2-ethoxyethyl)-
  • trm-986
  • umirolimus
  • umirolimus
  • umirolimus

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02446730Phase 4Sep 1, 2014Chonnam National University
NCT02193971Phase 4Jul 1, 2014Boston Scientific Corporation, Seoul National University, Terumo Corporation
NCT03056118Phase 4May 2, 2011Yonsei University
NCT01502904Phase 4Jul 1, 2010Yonsei University
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Yonsei UniversityAcademic/Hospital2212010
Boston Scientific CorporationFor profit1012014
Chonnam National UniversityAcademic/Hospital1112014
Seoul National UniversityAcademic/Hospital1112014
Terumo CorporationFor profit1012014
5 organizations
Page 1 / 1